Every material Form 8-K ESTABLISHMENT LABS HOLDINGS INC. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Establishment Labs reported third-quarter 2026 revenue of $72.0 million, up 33.9% from a year earlier, with U.S. revenue up 119.0% to $26.0 million. The company also raised its full-year 2026 revenue guidance to more than $274 million, from $269 million to $271 million, and reported its first positive quarter of free cash flow, which matters to shareholders because it shows higher sales and a narrower loss.
Q3 2026 revenue was $72.0 million versus $53.8 million in Q3 2025; GAAP net loss narrowed to $10.7 million, or $(0.35) per share, from $11.1 million, or $(0.38) per share.
Adjusted EBITDA was $6.4 million, or 8.9% of revenue, compared with $1.2 million a year earlier.
Free cash flow was $5.1 million in the quarter, the first positive quarter in the company's history.
Full-year 2026 revenue guidance was raised to more than $274 million; adjusted operating expense guidance of $195 million to $200 million was unchanged.
Establishment Labs, through its subsidiary ELSA, signed Amendment No. 3 to its Master Supply Agreement with NuSil Technology LLC, effective January 1, 2027. The amendment extends the initial term from December 31, 2026 to December 31, 2031, with automatic one-year renewals for up to five terms unless either party gives notice. The filing does not disclose financial terms, so its effect on shareholders is limited to supply continuity and contract terms.
Initial term of the supply agreement extended from December 31, 2026 to December 31, 2031
Automatic one-year renewals for up to five successive terms unless either party gives notice by December 31 before expiration
Amendment also covers medical-grade silicone supply, payment terms, business continuity, intellectual property and pricing provisions
Establishment Labs reported second-quarter 2026 revenue of $67.5 million, up 31.7% from a year earlier, and raised its revenue guidance to $269 million to $271 million. The net loss narrowed to $11.7 million from $16.6 million, and adjusted EBITDA turned positive at $3.7 million, which supports the company's revenue growth and improved profitability.
Q2 2026 revenue was $67.5 million, up 31.7% from $51.3 million in Q2 2025.
Revenue guidance was raised to $269 million to $271 million, up from $266.5 million to $268.5 million.
Net loss was $11.7 million, or $0.39 per share, compared with $16.6 million, or $0.57 per share, a year earlier.
Adjusted EBITDA was income of $3.7 million, compared with a loss of $8.5 million in Q2 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ESTABLISHMENT LABS HOLDINGS INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →